Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, announced today that over-the-counter Claritin has the potential to significantly reduce the nonsedating antihistamine prescription market. The information is detailed in primary research available from Decision Resources. The research includes surveys of 70 U.S.-based high-prescribing primary care physicians and eight pharmacy directors of large HMOs discussing the impact Claritin's patent expiry will have on the market for antihistamines. The report entitled The Impact of OTC and Generic Loratadine on the Treatment of Allergic Rhinitis also reveals that physicians' use of Scherling-Plough's Clarinex will increase if Claritin's over-the-counter switch is approved.

(Photo: NewsCom: )

"The approval of an over-the-counter designation for Claritin has the potential to significantly improve the drug line of managed care companies' budgets," said Matthew Bonner, MD, analyst at Decision Resources. "Although the availability of over-the-counter Claritin could permit the removal of the entire nonsedating antihistamine class from formularies, the backlash from patients -- forced to shoulder the full cost out-of-pocket -- and their employers could be formidable."

About Allergic Rhinitis

Allergic Rhinitis is a general term used to describe any allergic reaction of the nasal mucosa; it may occur perennially or seasonally. Allergic rhinitis is a common problem in the United States across all age groups and represents a considerable burden for payer groups. Analysis of claims data from a large insurer in the northeastern United States reveals that in 1999, 5% of the total insured population received some medical services for allergic rhinitis. Of those patients carrying this diagnosis, 42% received at least one prescription for an antihistamine.

About PhysicianForum

PhysicianForum is a new primary research service from Decision Resources. The service offers access to high-volume-prescribing primary care physicians, specialists and manage care representatives in the United States and Europe; analysis of events and responses to them; insight into prescribing patterns; and predictions for the pharmaceutical market based on the results.

About Decision Resources

Decision Resources, Inc. is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. The Company has provided strategic information services for 30 years, assessing international pharmaceutical and health care industry trends. Visit Decision Resources at

All company brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

   For more information, contact:    Elizabeth Marshall    Decision Resources    781-296-2563 


Photo: NewsCom:

AP Archive:

PRN Photo Desk, 888-776-6555 or 212-782-2840

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, +1-781-296-2563,

New Report Finds That HMO Enrollment Continues To Decline

View Now